A Phase I/II Trial of the Combination Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia

Conclusion Our study found that the combination of GO with azacitidine is relatively well tolerated, with similar response rates to GO monotherapy at higher doses. Differences in GO drug schedule, dose level and frequency may explain discrepant response rates between our study and others, suggesting that the optimal GO dose remains unclear, especially when combined with HMA therapy. Teaser In view of the single-agent activity of azacitidine and gemtuzumab ozogamicin (GO) in patients with relapsed acute myeloid leukemia (AML), a combination strategy was studied in this phase I/II trial to potentially further improve outcomes. GO/azacitidine therapy is relatively well tolerated and results in similar response rates compared to GO used in monotherapy at higher doses.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research